Volume 4.14 | Apr 12

Mammary Cell News 4.14 April 12, 2012
Mammary Cell News
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
ErbB Receptor Tyrosine Kinase/NF-κB Signaling Controls Mammosphere Formation in Human Breast Cancer
Researchers’ findings illustrate that heregulin/ErbB3 signaling appears to maintain mammosphere formation through a phosphatidyl inositol 3-kinase/NF-κB pathway in human breast cancer. [Proc Natl Acad Sci USA] Abstract

[Free Webinar] ALDH+ Cancer Precursor Cells in Drug Response Prediction - Register Now.
PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

RANK Induces Epithelial-Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
Investigators demonstrated that the RANK pathway promotes the development of mammary stem cells and breast cancer. [Cancer Res] Abstract

Eukaryotic Initiation Factor 4E Suppression in Breast Cancer Affects Maintenance and Progression
Scientists utilized transgenic and allograft breast cancer models to demonstrate that increased mammalian target of rapamycin signaling can be a significant contributor to breast cancer progression in vivo. [Oncogene] Abstract

Clinical and Functional Significance of Loss of Caveolin-1 Expression in Breast Cancer-Associated Fibroblasts
Researchers tested the hypothesis that loss of caveolin-1 expression in breast fibroblasts was associated with poor prognosis in breast cancer, through promotion of breast cancer cell invasion. [J Pathol] Abstract

B-Cell Translocation Gene 2 (BTG2) Stimulates Cellular Antioxidant Defenses through the Antioxidant Transcription Factor NFE2L2 in Human Mammary Epithelial Cells
Scientists reported that BTG2 protects human mammary epithelial cells from oxidative stress due to hydrogen peroxide and other oxidants. [J Biol Chem] Abstract

Gr-1+CD11b+ Cells Are Responsible for Tumor Promoting Effect of TGF-β in Breast Cancer Progression
Using 4T1 mammary tumor model that shares many characteristics with human breast cancer, researchers demonstrated that Gr-1+CD11b+ cells or myeloid derived suppressor cells are important mediators in TGF-β regulation of mammary tumor progression. [Int J Cancer] Abstract

Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways
Scientists investigated the molecular mechanism by which methylsulfonylmethane inhibits breast cancer growth in mice xenografts. [PLoS One] Abstract

Inhibition of Constitutively Activated Phosphoinositide 3-Kinase/AKT Pathway Enhances Antitumor Activity of Chemotherapeutic Agents in Breast Cancer Susceptibility Gene 1-Defective Breast Cancer Cells
Researchers reported that the phosphoinositide 3-kinase/AKT pathway is constitutively active in breast cancer susceptibility gene 1-defective human breast cancer cells. [Mol Carcinog] Abstract

N-(4-Hydroxyphenyl)Retinamide Inhibits Breast Cancer Cell Invasion through Suppressing NF-KB Activation and Inhibiting Matrix Metalloproteinase-9 Expression
Investigators show that N-(4-hydroxyphenyl)retinamide blocks the activity of matrix metalloproteinase-9 (MMP-9) in two ways: by reducing phorbol 12-myristate 13-acetate-induced MMP-9 secretion and by suppressing cell invasion through the downregulation of MMP-9 gene transcription in MCF-7 breast cancer cells. [J Cell Biochem] Abstract

CLINICAL RESEARCH

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
This is a noncomparative, randomized, phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib in patients with human epidermal growth factor receptor 2-positive, stage II to IIIA operable breast cancer. [J Clin Oncol] Abstract

Risk of Breast Cancer After False-Positive Test Results in Screening Mammography
Investigators used data from a long-standing population-based screening mammography program to determine the long-term risk of breast cancer in women with false-positive tests. [J Natl Cancer Inst] Abstract

Tamoxifen Alters the Plasma Concentration of Molecules Associated with Cardiovascular Risk in Women with Breast Cancer Undergoing Chemotherapy
Researchers evaluated the effect of tamoxifen on blood markers that are associated with cardiovascular risk in women undergoing chemotherapy for breast cancer. [Oncologist] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response

SCIENCE NEWS
Researchers Develop a New Cell and Animal Model of Inflammatory Breast Cancer
In an effort to better understand the biology of inflammatory breast cancer, researchers have developed a new cell and animal model that holds promise for providing a detailed understanding of the molecular mechanisms underlying the disease and for developing effective interventions. [Press release from the Fox Chase Cancer Center discussing research presented at the American Association for Cancer Research (AACR) Annual Meeting 2012, Chicago] Press Release
INDUSTRY NEWS

Mayo Clinic Launches Whole Genome Breast Cancer Study
The Breast Cancer Genome Guided Therapy Study will help physicians tailor chemotherapy to breast cancer patients based on their individual genomes and the genomes of their tumors. [Mayo Foundation for Medical Education and Research] Press Release

Syndax Pharmaceuticals Announced Start of Phase I/II Study of Entinostat in Combination with Lapatinib in HER2‐Positive Metastatic Breast Cancer
Syndax Pharmaceuticals, Inc. announced that investigators at The University of Texas MD Anderson Cancer Center have initiated a multi-center phase I/II study combining Syndax’s lead product entinostat with lapatinib ditosylate in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab. [Syndax Pharmaceuticals, Inc.] Press Release

PerkinElmer Launches HER2Sense™ Discovery Research Imaging Agent to Enable Personalized Medicine Approaches for Breast Cancer Research
PerkinElmer, Inc. announced the availability of the HER2Sense™ preclinical imaging agent, to support breast cancer discovery research into personalized medicine. [PerkinElmer, Inc.] Press Release

Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering Its Adva-27a Anti-Cancer Compound
Sunshine Biopharma Inc. announced that it has received notification that the United States Patent and Trademark Office has issued a Notice of Allowance for the patent application covering its lead anti-tumor compound, Adva-27a. [Sunshine Biopharma Inc.] Press Release

POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS

NEW European School of Oncology: Breast Cancer in Young Women (BCY1) Conference
November 8-11, 2012
Dublin, Ireland

Visit our events page to see a complete list of events in the mammary cell community.

JOB OPPORTUNITIES

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)


Scientist – Hematology (STEMCELL Technologies, Inc.)

Scientist – hPSC (STEMCELL Technologies, Inc.)


Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)


Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Fellow and Technician Positions (North Carolina Central University)

Postdoctoral Position – Breast Cancer/Stem Cell Biology (University of Cincinnati – College of Medicine)

Postdoctoral Research Fellow (Cancer Research UK – Cambridge Research Institute) 

Post-Doctoral Position – Translational Breast Cancer Research (ISREC/EPFL)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us